Please cite this article in press Enas H. Alfalogy, Depression Or Dementia Is Related More To Alzheimer’s Disease (AD) , Indo Am. J. P. Sci, 2023; 10 (09).

1. Nathan Falk and Ariel Cole. Evaluation of Suspected Dementia. Am Fam Physician. 2018;97(6):398-405.
2. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2017. 13:325-373.
3. Pnnce M. Bryce R. Albanese E. W1mo A. R 1 be1ro W and Fern CP. The global prevalence of dementia a systematic review and meta-analysis Al zhei­mers Dement. 2013,9(1) 63-75 e2
4. Melrose S. Recognizing and Responding to Depression in Dementia. SM J Psychiatry Ment Health. 2017; 2(1): 1008.
5. Thomas Leyhe, Charles F., Reynolds, Tobias Melcher, Christoph Linnemann, Stefan Klöppel, Kaj Blennow, Henrik Zetterberg, Bruno Dubois, Simone Lista, and Harald Hampel. A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer’s & Dementia. (2017) 59-71.
6. Naismith SL, Norrie LM, Mowszowski L, Hickie IB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology, 2010;75:27–34.
7. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s’s disease in the United States. Alzheimer’s Dement. 2017 Nov 29. [Medline].
8. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimer’s Dement. 2017 Nov 29. [Medline].
9. Alzheimer’s Association. Alzheimer’s’s Disease Facts and Figures. Alzheimer’s Dement 2018;14(3):367-429.
10. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: Final data for 2014. National Vital Statistics Reports. June 30, 2016. Available at https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf.
11. Heron M. Deaths: Leading Causes for 2014. National Vital Statistics Reports. June30,2016. Available at https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_05.pdf.
12. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009 May 28. 360(22):2302-9. [Medline]. [Full Text].
13. Shaheen E Lakhan. Alzheimer’s Disease. Updated: Jan 09, 2019 https://emedicine.medscape.com/article/1134817
14. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007. 29(1-2):125-32.
15. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015 Dec. 86 (12):1299-306. [Medline].
16. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer’s disease. Cold Spring Harb Perspect Biol. 2011 Sep. 3(9): a006189. [Medline].
17. Elshahidi MH. Prevalence of dementia in Egypt: a systematic review. 2017:(13) 715—720.
18. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 2018 Mar. 17 (3):241-250. [Medline].
19. Swerdlow RH, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: an update. Exp Neurol. 2009 Aug. 218(2):308-15. [Medline]. [Full Text].
20. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer’s disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011 Nov. 70(11):960-9. [Medline].
21. Braak H, Braak E, Grundke-Iqbal I, Iqbal K. Occurrence of neuropil threads in the senile human brain and in Alzheimer’s’s disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett. 1986 Apr 24. 65(3):351-5. [Medline].
22. Davinelli S, Intrieri M, Russo C, Di Costanzo A, Zella D, Bosco P, et al. The “Alzheimer’s disease signature”: potential perspectives for novel biomarkers. Immun Ageing. 2011 Sep 20. 8:7. [Medline]. [Full Text].
23. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimer’s Dis. 2010. 20 Suppl 2:S453-73. [Medline].
24. Hughes S. Beta-Blockers Linked to Fewer Alzheimer’s Lesions. Available at http://www.medscape.com/viewarticle/777239. Accessed: January 15, 2013.
25. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010 Apr. 9(2):132-9. [Medline].
26. . World Health Organization. Dementia. 2017.
27. Steffens DC, Potter GG. Geriatric depression and cognitive impairment. Psychol Med 2008;38:163–75.
28. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization; 2007.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association; 2013.
30. G. Cipriani C., Lucetti C., Carlesi S., Danti A., Nuti Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB. Depression and dementia. A review European Geriatric Medicine Volume 6, Issue 5, October 2015, Pages 479-486.
31. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB,
32. Farlow MR, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiatry 2003;160:857–66.
33. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003; 15:346–53.
34. Kida J1,2, Nemoto K3, Ikejima C4, Bun S1, Kakuma T5, Mizukami K3, Asada T3. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer’s Disease: A Community-Based Longitudinal Study. Alzheimer’s Disease. 2016;51(2):405-15.
35. Lauriola M. a Late-Life Depression versus Amnestic Mild Cognitive Impairment: Alzheimer’s Disease Incidence in 4 Years of Follow-Up. 2018;46:140–153.
36. Sara Garcıa-Herranz*, M. Carmen Dıaz-Mardomingo and Herminia Peraita. Neuropsychological predictors of conversion to probable Alzheimer’s disease in elderly with mild cognitive impairment. Journal Neuropsychology (2016), The British Psychological Society, 10, 239–255.
37. Sacuiu, Simona, Insel, Philip S., Mueller, Susanne, Tosun, Duygu, Mattsson, Niklas, Jack, Clifford R. DeCarli, Charles, Petersen, Ronald g, Aisen, Paul Weiner, Michael W. Mackin, R. Scott. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer’s Dementia. The American Journal of Geriatric Psychiatry February 2016 24(2):126-135.
38. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011;7:323–31.
39. Naismith SL, Norrie LM, Mowszowski L, Hickie IB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology, 2010;75:27–34.
40. Kuan. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild 18 cognitive impairment: Fflorbetapir (AV-45/Amyvid) PETstudy. Eur J Nucl Med Mol Imaging (2016) 43:1067–1076
41. Elvira Lara. The Impact of Depression on the Development of Mild Cognitive Impairment over 3 Years of Follow-Up: A Population-Based Study. Dement Geriatr Cogn Disord 2017;43:155–169.
42. Park JH, Lee SB, Lee TJ et al. Depression in vascular dementia is quantitatively and qualitatively different from depression in Alzheimer’s’s disease. Dement Geriatr Cogn Disord 2007;23:67-73.
43. Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas 2014;79(2):184-90 4
44. Ownby RL, Crocco E, Acevedo A et al. Depression and risk for Alzheimer’s disease: systematic review, metaanalysis, and meta regression analysis. Arch Gen Psychiatry2006;63:530-38 5
45. Da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova Ladinska EB. Affective disorders and risk of developing dementia: systematic review. B rJ Psychiatry 2013;202 (3):177-86.
46. Gao Y, Huang C, Zhao K et al. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. In tJ Geriatr Psychiatry 2013;28(5):441-49.
47. Barnes DE, Yaffe K, Byers AL et al. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer’s disease and vascular dementia. Arch Gen Psychiatry 2012;69(5):493-38
48. Butters MA, Young JB, Lopez O et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci2008;10:345-57
49. Brommelhoff JA, Gatz M, Johansson B et al. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychol Aging 2009;24(2):373-84
50. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011;7(6):323-31
51. Pnnce M. Bryce R. Albanese E. W1mo A. R 1 be1ro W, Fern CP. The globa I prevalence of dementia a systematic review and metaana lysis Al zhei­ mers Dement. 2013,9(1) 63-75 e2
52. Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J A m GerSoc 2005;53 (4):695-99Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. “Vascular depression” hypothesis. Arch Gen Psychiatry 1997;54:915–22.
53. Krishnan KR, Hays JC, George LK, Blazer DG. Six-month outcomes for MRI-related vascular depression. Depress Anxiety 1998;8:142–6.
54. Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc 2003;51:1178–80.
55. Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 2008;10:345–57.
56. Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biol Psychiatry 2006;60:1304–5.
57. Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM, Epstein AA, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry 2008;165:524–32.
58. Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety 2010;27:327–38.
59. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J. Major depression, cognitive dysfunction and Alzheimer’s disease: is there a link? Eur J Pharmacol 2010;626:72–82.
60. van de Pol LA, Hensel A, Barkhof F, Gertz HJ, Scheltens P, van der Flier WM. Hippocampal atrophy in Alzheimer’s disease: age matters. Neurology 2006;66:236–8.
61. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957–66.
62. Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, et al. Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res 2007;41:553–60.
63. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s’s disease. Lancet 2006;368:387–403.
64. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer’s disease. Nat Rev Neurol 2010; 6:131–44.
65. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010;626:64–71.
66. Sophia Bennett and Alan J.Thomam. Depression and dementia: Cause, consequence or coincidence? volume 79, Issue 2, October 2014, Pages 184-190
67. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta amyloid peptides and increases neuronal survival. Exp Neurol 2007; 203:274–8.
68. Lezoualc’h F. 5-HT4 receptor and Alzheimer’s disease: the amyloid connection. Exp Neurol 2007;205:325–9.
69. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297:353–6.
70. Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol 2010;68:446–53.
71. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27–53.
72. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer’s disease with comorbid depression. Am J Geriatr Psychiatry 2008; 16:168–74.
73. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, et al. Increased hippocampal plaques and tangles in patients with Alzheimer’s disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161–7.
74. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res 2007;32:1749–56.
75. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuro inflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res 2008;39:1–16.
76. Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007;21:259–72.
77. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, well-functioning61:76–80.
78. Fumagalli F, Molteni R, Calabrese F, Maj PF, Racagni G, Riva MA. Neurotrophic factors in neurodegenerative disorders: potential for therapy. CNS Drugs 2008;22:1005–19.
79. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455:894–902.
80. Karege F1, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in post-mortem brains of suicidevictims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005;136:29–37.
81. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005; 10:345–52.
82. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s’s disease and Parkinson’s disease. Prog Neurobiol 2001;63:71–124.
83. Cotman CW. The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 2005;30:877–81.
84. Verhoeven JE, Revesz D, Epel ES, Lin J, Wolkowitz OM, Penninx BW. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry 2014;19:895–901.
85. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer’s’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560–74.
86. Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimer’s Dement 2012;8:312–36.
87. Lista S, Khachaturian ZS, Rujescu D, Garaci F, Dubois B, Hampel H. Application of systems theory in longitudinal studies on the origin and progression of Alzheimer’s Disease. Methods Mol Biol 2016; 1303:9–67.
88. Cordell CB, Borson S, Boustan1 M, et al, Med1care Detect1on of Cognitive impairment Workgroup Alzheimer’s Association recommendations for the detect1on of cogn1t1ve 1mpa1rment during the Med1care Annual Wellness Vis1t 1n a primary care setting Alzheimer’s Dement. 2013,9(2) 141-150
89. Lin JS. O’Connor E. Rossom RC, et al Screening for cognitive impairment in older adults: an ev1dence update for the U.S. Preventive Services Task Force Ev1dence syntheses. No 107 Rockville. Md Agency for Healthcare Research and Quality, 2013. https//www.ncbrnlm.n1h gov/books/NBK174643/ Accessed October 18. 2017
90. Velayudhan L. Ryu SH. Raczek M. et al. Review of brief cognitive tests for pat1ents w1th suspected dementia . lnt Psychogenatr 2014.26(8) 1247-1262
91. Galvin JE. Sadowsky CH. NINCDS-ADRDA Practical guidelines for the recogn1t1on and d1 agnos1s of dement1a JAm Board Fam Med2012:25(3) 367-382
92. American Psychiatric Association. Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013. 611-614.
93. Moore A, Frank C, Chambers LW. Role of the family physician in dementia care. Can Fam Physician. 2018;64(10):717–719.
94. Moore A, Patterson C, Lee L, Vedel I, Bergman H. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Recommendations for family Physicians. Can Fam Physician. 2014;60:433–8. (Eng), e244–50 (Fr). [PMC free article] [PubMed] [Google Scholar]
95. Frank C, Wilson RC. Models of primary care for frail patients. Can Fam Physician. 2015;61:601–6.[PMC free article] [PubMed] [Google Scholar]
96. Moore A, Patterson C, White J, House ST, Riva JJ, Nair K, et al. Inter professional and integrated care of the elderly in a family health team. Can Fam Physician. 2012;58:e436–41. Available from: www.cfp.ca/content/cfp/58/8/e436.full.pdf. Accessed 2018 Aug 13. [PMC free article] [PubMed] [Google Scholar]
97. Steptoe A, Deaton A, Stone AA. Subjective wellbeing, health and ageing. Lancet. 2015;385(9968):640–8. Epub 2014 Nov 6. [PMC free article] [PubMed] [Google Scholar]
98. Livingston G, Sommerlad A, Orgeta V, Costafreda S, Huntely J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734. Epub 2017 Jul 20. [PubMed] [Google Scholar]
99. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. LancetNeurol. 2014;13(8):788–94. Lancet Neurol 2014;13(11):1070. [PubMed] [Google Scholar]